Chuck Alpuche Appointed to President and COO of Imperative Care
Chuck Alpuche was appointed President and Chief Operating Officer of Imperative Care.
Pioneering Medical Innovations
Pioneering Medical Innovations
Chuck Alpuche was appointed President and Chief Operating Officer of Imperative Care.
The FDA granted 510(k) clearance for the Zoom 7X Catheter, the first catheter featuring CenTRX Technology for enhanced navigation and asymmetric clot ingestion, with first patient cases completed.
A late-breaking abstract at the SNIS 2025 annual meeting reported strong reperfusion and safety results with the Zoom System in stroke patients with M2 vessel occlusions.
Tyler Binney joined Imperative Care’s Board of Directors.
Enrollment was completed in the SYMPHONY-PE IDE study evaluating the Symphony Thrombectomy System for acute pulmonary embolism.
Imperative Care launched the Zoom DuoPort technology, enabling the Continuous Dual Aspiration Technique (CDAT) with two Zoom Aspiration Catheters running simultaneously from a single vacuum source, and announced the first patients treated.
Todd Van Horn was appointed Chief Financial Officer of Imperative Care.
The company will fund an investigator-initiated randomized trial comparing continuous dual aspiration thrombectomy with the Zoom Stroke System plus best medical treatment versus best medical treatment alone for M2 occlusions.
Imperative Care expanded its Symphony thrombectomy portfolio with a design purpose-built for treating venous thrombosis.
The FDA granted 510(k) clearance for the Zoom System, the first comprehensive stroke thrombectomy system to include large-bore .088-inch catheters indicated for both access and aspiration, supported by final Imperative Trial data.